INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • October 21st, 2019 • Kazia Therapeutics LTD • Pharmaceutical preparations • Massachusetts
This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the _I7* day of October. 20LS (“Effective Date”) between Kazia Therapeutics Ltd (ACN 063 259 754) a company incorporated in Australia with a principal place of business at 1.24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”), and Dana-Farber/Partners Cancer Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of business at 44 Binney Street, Boston, MA 02115 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH FUNDING AND SUPPLY AGREEMENTResearch Funding and Supply Agreement • October 21st, 2019 • Kazia Therapeutics LTD • Pharmaceutical preparations • Illinois
This Agreement (the “Agreement”), effective as of _June 11, 2019 (“the Effective Date”), by and between Alliance for Clinical Trials in Oncology Foundation, an Illinois not-for-profit corporation, with its principal office at 125 S. Wacker Drive, Chicago, IL 60606 (“Foundation”) and Kazia Therapeutics Limited (ABN 37 063 259 754), a publicly-listed company with its principal office at L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Kazia”). Kazia and Foundation may be referred to as “Party” individually, and collectively as the “Parties”.
Master Clinical Trial AgreementMaster Clinical Trial Agreement • October 21st, 2019 • Kazia Therapeutics LTD • Pharmaceutical preparations • New York
A Kazia is a global biotechnology company engaged in the research and development of therapeutic products or devices for patients with cancer.
